{"status":"success","data":{"title":"Post-Exposure Prophylaxis, non-occupational contact","slug":"post-exposure-prophylaxis","tags":null,"collection":["infectious disease"],"content":"\n# Post-Exposure Prophylaxis (PEP): Non-Occupational Contact\n\n**National Clinicians’ Post-Exposure Prophylaxis Hotline of the National HIV/AIDS Clinicians’ Consultation Center**\n\n-   **Phone:** [1-888-448-4911](tel:8884484911%20) (24 hrs/day)\n-   To consult on occupational AND non-occupational exposure to HIV\n\n## Baseline Testing of Exposed Patient\n\n-   HIV\n-   Hepatitis B (specifically HBsAb for immunity) \n-   Hepatitis C antibody \n-   Gonorrhea\n-   Chlamydia \n-   Syphilis\n-   CBC\n-   Creatinine\n-   LFT\n-   Pregnancy, if appropriate \n\n## Risk of HIV\n\n-   Receptive anal intercourse: 1-30% risk\n-   Insertive anal or receptive vaginal intercourse: 0.1-10% risk\n-   Oral intercourse: “very low risk” but not zero risk\n-   Needle sharing with injection drug use: 0.67% per needle-sharing contact \n\n## High-Risk Source Patient\n\n-   Known HIV+ source patient \n-   High-risk populations\n-   Men who have sex with men+/-women\n-   Commercial sex workers\n-   Injection drug users\n-   History of incarceration\n-   From a country with HIV seroprevalence ≥ 1%\n-   Persons with sexual partner in this high-risk population group \n\n## If Decide to Give PEP for Possible HIV Exposure\n\n-   **Timing:** The sooner the treatment, the better. Starting treatment ≤ 48 hours after exposure is best. Still eligible if present ≤ 72 hours per CDC.\n-   **Effectiveness:** PEP is associated with 81% decrease in HIV transmission.\n-   **Duration of treatment** = 28 days\n\n**TREATMENT OPTIONS:**\n\nOption \\#1: **Combivir** (300 mg <span class=\"drug\">zidovudine</span>-150 mg <span class=\"drug\">lamivudine</span>)- 1 tab po BID\n\n  - Side Effects:\n  - Nausea\n  - Anemia\n  - Hepatotoxic\n  - Neutropenia\n  - Asthenia\n\nOption \\#2: **Truvada** (300 mg <span class=\"drug\">tenofovir</span>-200 mg <span class=\"drug\">emtricitabine</span>) – 1 tab po Qday (Side effects: Nephrotoxic)\nFor very high-risk exposure: Can add to Option \\#1 or \\#2:\n-   **Kaletra (<span class=\"drug\">ritonavir</span>-<span class=\"drug\">lopinavir</span>)** (Side effects: Hepatotoxic, diarrhea), or\n-   **<span class=\"drug\">Ritonavir</span>** plus **<span class=\"drug\">Atazanavir</span>** \n\n  - Side Effects:\n  - Hepatotoxic\n  - jaundice\n  - renal stones\n\n-   **<span class=\"drug\">Ritonavir</span>** plus **<span class=\"drug\">Darunavir</span>** (Side effects: Hepatotoxic, diarrhea)\n\n**Followup HIV and syphilis test at 4-6 weeks, 3 months, 6 months post-exposure**\n\n## Additional Treatment\n\n[CDC Sexual Assault and STD website](http://www.cdc.gov/std/treatment/2010/sexual-assault.htm)\n\n-   **<span class=\"drug\">Ceftriaxone</span>** 250 mg IM x 1 (for Gonorrhea) - or can give IV\n-   **<span class=\"drug\">Azithromycin</span>** 1 g po x 1 (for Chlamydia)\n-   **<span class=\"drug\">Metronidazole</span>** 2 g po x 1 (for trichomonas)\n-   Consider **emergency contraception** for women\n-   **Hep B vaccination**, if not fully vaccinated – need to finish series at 1-2 & 4-6 mo \n\n## References\n\n-   [Landovitz RJ, Currier JS. Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med. 2009 Oct 29;361(18):1768-75.](http://www.ncbi.nlm.nih.gov/pubmed/?term=19864675)\n"}}